T细胞能够识别的肿瘤抗原，多数由MHC呈递后于TCR结合，激活T细胞活性。然而，肿瘤抗原-MHC复合体与TCR的亲和力很弱。所以通过肿瘤抗原-MHC形成四聚体，增强与TCR的结合能力。MHC只有结合适宜的抗原多肽，才能正确地表达于抗原呈递细胞表面，从而被T细胞识别并结合。
肿瘤抗原-MHC四聚体复合物结合荧光，通过流式细胞荧光分选，从而捕获抗原特异性T细胞。因此，肿瘤抗原-MHC四聚体有如下部分构成：
MHC类型(HLA)+突变抗原肽序列+荧光标记(可选APC/FITC/PE)
肿瘤抗原MHC四聚体复合物现货产品：
| 抗原名称 | 产品数量 |
|---|---|
| hTERT | 18 |
| p53 | 17 |
| human CLIP103-117 | 16 |
| Tyrosinase | 11 |
| Control | 9 |
| gp100 | 8 |
| MAGE-A1 | 7 |
| Mesothelin | 6 |
| NY-ESO-1 | 6 |
| GPC3 | 6 |
| IGRP | 6 |
| Negative | 5 |
| MUC1 | 5 |
| PSA | 5 |
| H-Y | 5 |
| MAGE-A3 | 5 |
| MAGE-A2 | 4 |
| Her-2/neu | 3 |
| IAPP | 3 |
| Survivin18-27 (modK) | 3 |
| topo II | 3 |
| CD20 | 3 |
| LY6K | 3 |
| PSMA | 3 |
| EZH2 | 3 |
| gp100 (mutant) | 3 |
| NY-ESO-1 C9V | 3 |
| Her-2/neu E75 | 3 |
| PR-1 | 3 |
| BA46 | 3 |
| PSCA | 3 |
| modified WT1 | 3 |
| Survivin | 3 |
| BCR-ABL | 3 |
| Insulin B | 3 |
| gp100 (wild) | 3 |
| LIVIN | 3 |
| Mart-1 | 3 |
| PRAME300-309 | 2 |
| WT1126-134 | 2 |
| SSX-2 | 2 |
| gp100-intron 4 | 2 |
| PP2A | 2 |
| CD33 A65Y | 2 |
| Fel d 149-66 | 2 |
| MAGE-A3 112-120 | 2 |
| survivin-2B | 2 |
| MAGE-A3 271-279 | 2 |
| Human MR1 | 2 |
| MAGE-C1 | 2 |
| PRAME100-108 | 2 |
| ACC-1 | 2 |
| BTG1 | 2 |
| measles virus HA | 2 |
| RHAMM | 2 |
| CEA | 2 |
| Survivin (T2M) | 2 |
| CEA (N6D) | 2 |
| TT p2829-844 | 2 |
| Mtb 16 kDa | 2 |
| MAGE-A10 | 2 |
| Mtb 19 kDa | 2 |
| PAP 299-307 | 2 |
| Mtb Ag85A242-250 | 2 |
| EphA2 | 2 |
| Mtb Ag85A48-56 | 2 |
| PRAME142-151 | 2 |
| Mtb Ag85B | 2 |
| PRAME425-433 | 2 |
| Mtb Ag85C | 2 |
| PSA141-150 | 2 |
| Mtb ESAT-6 | 2 |
| GAD65555-567 | 2 |
| Mtb Hsp65 | 2 |
| RNA-dependent helicase | 2 |
| Mtb Rv1614 | 2 |
| CA9219-227 | 2 |
| Lol p 1105-117 | 2 |
| HM1.24 | 2 |
| AIM-2 | 2 |
| CLIP103-117 | 2 |
| CD33 | 2 |
| Human CD1d | 2 |
| WT137-45 | 2 |
| Bet v 1142-156 | 2 |
| P2X5 | 2 |
| WT-1126-134 | 1 |
| MPT51 | 1 |